Newborn infants have little or no secretory IgA (SIgA) at birth ... No study to date has examined SIgA production as a function of gestational age or examined the kinetics of SIgA acquisition ...

Secretory IgA is resistant to degradation and provides ... Postnatal maternal immunizations aimed to enhance breast milk antibodies production might be a promising approach. In addition to being ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...